Changing the course of cancer treatment

We harness the power of the body's immune system to keep tumor cells in check without harming health or quality of life.
<p>Middle aged man running in a field of grass, surrounded by mountains.</p>

Gaining the
upper hand

Today, tumor recurrence causes the vast majority of cancer-related deaths. We want to change this by designing new therapeutic options that tip the balance in favor of the immune system.

What we do

New ways to make a difference

We dare to shine the light of science down new and unexplored paths to improve the course of cancer treatment.

About us

Latest news

All news
Latest

Mendus to present novel data supporting the broad potential of its proprietary cancer vaccine platform at CICON23

Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, will present novel clinical and preclinical data on the mode of action of its...
Learn more

For investors

Invest in future cancer care

Mendus is listed on NASDAQ Stockholm under the ticker symbol IMMU. You will find all relevant information on the Mendus share in our Investors section.

Investors
<p>Close up of a middle aged woman dressed in a blazer, sitting down while looking at another person in the foreground.</p>

Latest presentation

Financial calendar

  • Publication of Year-end Report 2022

  • Publication of Annual Report 2022

  • Annual General Meeting

  • Publication of Q1 Report

  • Publication of Q2 Report

  • Publication of Q3 Report

  • Publication of Year-end Report 2023

Events

All events
Upcoming

Nordic Conference and Opening Ceremony of NorthX Innovation Hub

Mendus Board member Hans Preusting will participate at the event.

Learn more

A life-changing career

At Mendus, we share a strong commitment to improve the lives of people with cancer. And we do it as a team who values honesty and togetherness. Join us and help change cancer treatment at its core.

Careers